deCode's survival is vital for genetic research
This article was originally published in Clinica
deCode Genetics, a leading biomarker discovery company under its CEO Kari Stefansson, seems to be stuck between the devil and the deep blue sea. Either it sells its profit-making drug development outlets in the US to safeguard its leading complex traits genetics operations, only to face a very uncertain future in a diagnostics market that hasn’t quite made the transition into the personalised medicine world; or it faces an extremely rough ride in the current economic maelstrom, which has had particularly sharp repercussions in Iceland. The only way out seems to be a takeover by a well-heeled investor willing to preserve the company’s unique position of trust among Iceland’s population.